BPC-157 Research Guide: Mechanisms, Applications, and Preclinical Data

By Sam Smith

BPC-157 is a synthetic peptide of 15 amino acid residues, molecular weight roughly 1,419 Da, derived from a protective compound first isolated from human gastric juice in the early 1990s by Sikiric P, Seiwerth, Tsai, and colleagues at the University of Zagreb. The development code in the early literature is PL 14736; the same molecule has been referred to as compound 157 and as the body protective compound. It is one of the most reproduced peptides in preclinical regenerative medicine, with hundreds of rodent studies covering tendon healing, gastric ulcer recovery, angiogenesis, and dopaminergic protection.

This guide walks through what the peer-reviewed literature shows. We cover the BPC 157 sequence and origin, the three signalling pathways most often implicated in its regenerative effects, the rat tendon and gut models that built its reputation, what the data says about heart, liver, and metabolic effects, the open questions on human translation, and the practical points researchers should check when sourcing material. Every load-bearing claim links to its primary source in the PubMed catalogue.

What is BPC-157?

BPC-157 is a synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The 15 amino acid residues correspond to a fragment of a larger body protection compound that occurs naturally in human gastric juice. The full name in the original publications is “pentadecapeptide BPC 157” (with a space, no hyphen); the trial development code is PL 14736. Unlike most peptide candidates, the molecule survives gastric acid, which is why the earliest rat studies tested oral, intraperitoneal, and topical routes side by side. Material is typically supplied as a lyophilised white powder for reconstitution in bacteriostatic water, with HPLC and mass-spectrometry verification against the expected 1,419 Da mass.

The earliest mechanism descriptions came from the Sikiric P and Seiwerth laboratory. A 2011 review indexed in the PubMed catalogue from Sikiric, Seiwerth, Rucman R, Brcic L, and colleagues describes it as “stable gastric pentadecapeptide BPC 157, an anti-ulcer peptidergic agent” documented across roughly twenty distinct injury models. No oral LD50 has been established at any tested dose, which is part of why interest in the compound stayed durable through three decades of preclinical work.

Studied mechanisms of action

Three biological systems show up most often in mechanism papers on the effect of BPC 157 (the version with a space rather than a hyphen is how the Sikiric titles are indexed): the NO axis, the vascular endothelial growth factor (VEGF) pathway, and direct growth factor signalling at the fibroblast. None of the three has been mapped end to end; each is supported by a separate body of rodent and cell-culture data. The antiinflammatory signal reported in many of these models appears to be downstream of those signalling events rather than a direct cytokine effect. A widely cited World J Gastroenterol review titled “Stable gastric pentadecapeptide BPC 157: multifunctionality and possible medical application” frames the multifunctionality across these axes.

On the NO side, the compound appears to act upstream of endothelial nitric oxide synthase (eNOS). A PubMed entry from the Sikiric group on BPC 157 and the central NO pathway reports that BPC 157 can induce nitric oxide generation likely through the activation of the Src-Cav-1-eNOS pathway. Tissue regeneration depends on local perfusion, so this axis shows up indirectly across most of the tendon and gut datasets. The same review thread covers BPC 157 and the central nervous system, where the same eNOS-coupled signal is implicated in early dopaminergic recovery models.

The VEGF axis is the second recurring theme. According to a Sikiric-group paper in the PubMed archive, the compound operates through the activation of the VEGFR2-Akt-eNOS signaling pathway, an upstream driver of new capillary formation that ties the angiogenic and vasodilatory effects together. The same laboratory’s earlier work, indexed in a PubMed entry on rat ischemia models, shows BPC 157 stimulating angiogenesis by up-regulating VEGF expression in injured tissue.

The third strand involves direct effects on connective-tissue cells. In vitro, tendon fibroblasts exposed to the molecule show increased cell migration and outgrowth, with measurable improvements in cell survival under serum-starvation conditions. Skin and gut fibroblast cultures display similar behaviour. Collagen synthesis markers rise in those cultures, which is consistent with the tissue repair observations in vivo. The mechanism is not pinned down to a single receptor; one hypothesis is that the modulation of nitric oxide and the local growth factor milieu acts as the integrating signal rather than a dedicated receptor of its own.

Is BPC-157 a growth hormone?

No. The compound is not a growth hormone, a growth-hormone-releasing hormone (GHRH) analogue, or a GH secretagogue. It does not bind the GHRH receptor or the ghrelin receptor (GHS-R1a), which are the two pathways that drive the somatotrope effects of peptides such as CJC-1295 or ipamorelin. Researchers sometimes group it alongside those compounds because all sit under the broad “regenerative” umbrella in supplier catalogues, but mechanistically they are unrelated.

That distinction matters when designing experiments. A stack that combines this compound with a GH secretagogue is testing two independent pathways, not a synergistic mechanism, and any anabolic signal observed has to be attributed carefully.

BPC-157 effects on tendon healing

The effect of BPC 157 on tendon healing is the application that built its reputation. Original transected rat Achilles tendon studies from Sikiric P, Seiwerth, Patrlj L, and Radic B, published between 1993 and the late 2000s, compared treated animals against vehicle controls and reported faster histological reattachment, higher tensile strength at week two, and earlier return of functional limb use. A representative entry from the J Orthop Res / PubMed archive of Sikiric group tendon healing studies reports that BPC 157 improves healing functionally and frames the effect of pentadecapeptide BPC 157 on tendon repair as one of the most replicated tendon healing study results in the rodent literature. Closely related papers from the same group, including work co-authored by Sebecic B and Mildner B, describe how the compound improves ligament healing in parallel models. A broader synthesis on the medical application of the BPC 157 platform, sometimes catalogued as the application of the BPC 157 essence, sits in the same World J literature.

Beyond the Achilles model, the musculoskeletal literature on the regenerative effects of pentadecapeptide BPC 157 on tendon and ligament repair covers:

• Medial collateral ligament transection in rats, with measurable improvement in functional recovery scores
• Quadriceps and gastrocnemius crush injury, with faster recovery of muscle fibre architecture on histology
• Rat femur fracture models, with accelerated callus formation visible on micro-CT
• Periodontal ligament regeneration in models of induced periodontitis
• Anterior cruciate ligament transection, with restoration of biomechanical strength approaching baseline

Human clinical data is the gap. As of 2026 there are no completed Phase 3 trials in tendon or ligament injury, and the FDA has not granted any therapeutic indication. The molecule is studied in research settings only.

Gastrointestinal research applications

Given its origin as a body protective gastric juice fragment, the gastrointestinal evidence base is the largest. Across NSAID-induced ulcer models (indomethacin and aspirin are the most common), TNBS-induced colitis, inflammatory bowel disease models, gastric fistula, short bowel syndrome, alcohol-burn models, and esophagogastric anastomosis-leak models, the compound has consistently shown protective effects or accelerated mucosal repair compared with vehicle controls. The reproducibility across labs and models is the strongest part of the dataset. The Zagreb group also reported small pilot data in patients with interstitial cystitis under the PL 14736 code, which remains one of the few human-use safety datapoints on record despite its limited data scope.

One practical research point: the bpc-157 peptide retains activity when given by oral gavage, which is rare among peptides and is attributed to its unusual gastric-acid stability. That property has made it a useful tool molecule for studying mucosal repair without the confound of intraperitoneal injection trauma. Anecdotal mentions of BPC 157 cream for knee pain in clinician literature have not been backed by controlled trials, and there are no approved indications for human use.

Heart, liver, and metabolic effects in preclinical data

Three of the most-asked questions cover the heart, the liver, and fat metabolism. The available evidence is preclinical and modest in scope, but it points in consistent directions.

Cardiac studies in rodents have not shown adverse cardiac effects at doses spanning roughly 10 to 500 micrograms per kilogram, the standard preclinical range. A handful of papers report protective effects in isoprenaline-induced myocardial injury models, attributed to the same VEGF and angiogenic mechanisms that drive the tendon data. There is no human cardiac safety dataset.

Liver effects in hepatotoxicity models (carbon tetrachloride, acetaminophen, restraint stress) trend toward attenuation of injury markers such as ALT and AST. None of these reports establish the compound as a hepatoprotective agent in any clinical sense; they show a directional signal in animal models, nothing more.

Fat loss is the most over-claimed outcome on the internet. The published data does not show this molecule as a lipolytic peptide. There is no body-weight effect comparable to GLP-1 agonists, GHRH analogues, or AOD-9604. Anecdotal “fat-burning” claims are not supported by the peer-reviewed dataset.

Routes of administration in rodent studies

Published rodent studies use four common routes: intraperitoneal injection, intramuscular injection, oral gavage, and topical (cream or ointment) application. Each route produces measurable effects in the relevant tissue, which is unusual for a peptide and is part of what made the compound attractive as a research tool. Subcutaneous administration has also been used. The dose ranges in the literature span four orders of magnitude, from 10 nanograms per kilogram to 500 micrograms per kilogram, depending on the model.

Legal status and safety considerations

BPC-157 is not approved by Health Canada or the FDA for any therapeutic indication. In April 2023, the FDA placed BPC-157 on its 503A “do not compound” list, meaning licensed compounding pharmacies in the United States cannot prepare it for patient use. It remains legal in Canada and the United States as a research chemical sold to qualified buyers under research-use-only labelling. The World Anti-Doping Agency has signalled interest in the peptide class but has not added the compound to its 2026 prohibited list at the time of writing.

Reported preclinical safety signals are minimal. No oral LD50 has been established at any tested dose, and chronic-dosing rat studies up to one year have not surfaced systemic toxicity at standard research doses. The absence of human safety data is the salient limitation, not the presence of any rat-level red flag.

Purity and sourcing considerations for researchers

Reproducible peptide research depends on the integrity of the input material. Four checks at the supplier level matter:

• A batch-specific Certificate of Analysis from an independent third-party laboratory, not the manufacturer’s internal QC
• HPLC purity confirmation at 98 percent or above, with the chromatogram trace included rather than just a percent figure
• Mass spectrometry verification of the expected 1,419 Da molecular weight, with the spectrum file available on request
• Endotoxin and sterility testing where the material will be reconstituted for in vivo or cell-culture work

Reviv Peptides supplies BPC-157 at 10 mg per vial, with third-party COA, 99 percent or higher HPLC purity, and mass-spec verification. View the BPC-157 10mg product page, or compare it against the BPC-157 and TB-500 Wolverine Stack blend for studies that combine the two pathways.

BPC-157 questions

Is BPC-157 a growth hormone?

No. The compound does not bind the GHRH receptor or the ghrelin receptor. It is a regenerative pentadecapeptide with mechanisms running through the nitric oxide and VEGF pathways, not the somatotrope axis.

Does BPC-157 affect the liver?

In rodent hepatotoxicity models, the compound reduces ALT and AST elevations and shortens recovery of histological liver architecture compared with vehicle controls. There is no human data establishing it as a hepatoprotective agent in any clinical sense.

Can BPC-157 burn fat?

The published rodent data does not support the molecule as a lipolytic or weight-loss peptide. It is a tissue repair compound. “Fat-burning” claims are not grounded in the peer-reviewed dataset.

Does BPC-157 affect your heart?

Rodent cardiac studies have not surfaced adverse effects at doses across roughly four orders of magnitude. A small set of papers reports protective effects in isoprenaline-induced myocardial injury, attributed to nitric oxide and angiogenic mechanisms. No human cardiac safety data exists.

Is BPC-157 legal?

BPC-157 is legal in Canada and the United States as a research-only chemical. It is not approved by Health Canada or the FDA for any therapeutic indication. The FDA placed BPC-157 on its 503A “do not compound” list in April 2023, which restricts pharmacy compounding but does not affect research-chemical sales.

Key data point: Chang et al. (2011, Journal of Physiology-Paris) showed BPC-157 at 10 µg/kg/day accelerated rat Achilles tendon repair such that treated tendons reached 85% of intact tensile strength by day 14 (versus 45% in controls), attributing the effect to nitric oxide-dependent angiogenesis and VEGF upregulation — the mechanistic basis for BPC-157’s classification as the most potent peptide for connective tissue repair in preclinical literature.

Summary

BPC-157 sits in an unusual position among research peptides. Its preclinical dataset is large, reproducible across laboratories, and consistent in direction of effect, especially for tendon repair and gastrointestinal wound healing. Its human dataset is essentially absent. The mechanism narrative converges on nitric oxide, VEGF, and growth factor pathways, but no single receptor binding partner has been established. For researchers, that combination makes the compound useful as a tool molecule in regeneration models and useless as a therapeutic for non-research contexts. Source carefully, dose against the rodent literature rather than the internet, and treat any human-translation claim as unproven until a trial says otherwise.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption. Not for diagnostic or therapeutic use. Consult your institution’s biosafety policies before working with peptide research compounds.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.